{"disease":{"id":"progressive-multiple-sclerosis-pms","name":"progressive multiple sclerosis pms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07225504","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03387670","title":"Multiple Sclerosis-Simvastatin Trial 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":964,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03523858","title":"A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":927,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04593927","title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06961383","title":"Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"NeuroGenesis Ltd.","has_results":false},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT03696485","title":"Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Stem Cell Medicine Ltd.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}